Diagnostic capabilities and patient identification are critical determinants of the Castleman disease treatment market's ability to reach eligible patients and deliver timely, appropriate therapy. Castleman disease remains frequently misdiagnosed or delayed in diagnosis, with patients often enduring years of symptoms and multiple incorrect diagnoses before receiving appropriate treatment. The...